These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21976467)

  • 21. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review.
    Schackman BR; Eggman AA
    Curr Opin HIV AIDS; 2012 Nov; 7(6):587-92. PubMed ID: 23076124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention.
    White JM; Mimiaga MJ; Krakower DS; Mayer KH
    AIDS Patient Care STDS; 2012 Jul; 26(7):395-405. PubMed ID: 22694239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.
    Abbas UL; Glaubius R; Mubayi A; Hood G; Mellors JW
    J Infect Dis; 2013 Jul; 208(2):224-34. PubMed ID: 23570850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
    Murewanhema G; Malisheni M; Takah NF
    Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection?
    Pialoux G; Delaugerre C; Cotte L; Raffi F; Cua E; Molina JM
    Clin Microbiol Infect; 2016 Sep; 22(9):757-767. PubMed ID: 27615724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
    Noret M; Balavoine S; Pintado C; Siguier M; Brun A; Bauer R; Loze B; Leplatois A; Aslan A; Moudachirou K; Delaugerre C; Rozenbaum W; Molina JM
    AIDS; 2018 Sep; 32(15):2161-2169. PubMed ID: 30212403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
    Paltiel AD; Freedberg KA; Scott CA; Schackman BR; Losina E; Wang B; Seage GR; Sloan CE; Sax PE; Walensky RP
    Clin Infect Dis; 2009 Mar; 48(6):806-15. PubMed ID: 19193111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
    Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
    McGowan I
    Am J Reprod Immunol; 2014 Jun; 71(6):624-30. PubMed ID: 24635047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Animal models of antiretroviral prophylaxis for HIV prevention.
    García-Lerma JG; Heneine W
    Curr Opin HIV AIDS; 2012 Nov; 7(6):505-13. PubMed ID: 22964889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
    Dolling D; Phillips AN; Delpech V; Pillay D; Cane PA; Crook AM; Shepherd J; Fearnhill E; Hill T; Dunn D; ;
    HIV Med; 2012 May; 13(5):309-14. PubMed ID: 22151684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
    Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
    Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
    HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons.
    Pattacini L; Murnane PM; Baeten JM; Fluharty TR; Thomas KK; Bukusi E; Katabira E; Mugo N; Donnell D; Lingappa JR; Celum C; Marzinke M; McElrath MJ; Lund JM;
    J Infect Dis; 2015 Jun; 211(12):1943-52. PubMed ID: 25520426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Whatever is in the ARVs, is Also in the PrEP" Challenges Associated With Oral Pre-exposure Prophylaxis Use Among Female Sex Workers in South Africa.
    Makhakhe NF; Sliep Y; Meyer-Weitz A
    Front Public Health; 2022; 10():691729. PubMed ID: 35784260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
    van de Vijver DA; Boucher CA
    Curr Opin Infect Dis; 2010 Dec; 23(6):621-7. PubMed ID: 20847692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV Infection and Drug Resistance with Unsupervised Use of HIV Pre-Exposure Prophylaxis.
    Volk JE; Nguyen DP; Hare CB; Marcus JL
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):329-330. PubMed ID: 29262689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.